TMCnet News
Unum Therapeutics to Present on its Antibody-Coupled T-Cell Receptor (ACTR) Platform at the Upcoming 58th American Society of Hematology (ASH) Annual MeetingUnum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that the Company has been selected for two poster presentations on its Antibody-Coupled T-cell Receptor (ACTR) platform at the 58th ASH Annual Meeting, which is being held in San Diego, California, December 3-6, 2016. In addition, Dr. Michelle Poon of the NUH in Singapore, will be presenting initial results of an ongoing Investigator Sponsored Trial using autologous T-cells with ACTR transiently expressed through mRNA electroporation in combination with rituximab in patients with relapsed/refractory CD20+ B-cell Non Hodgkin lymphoma (B-NHL) (ATTCK20; ClinicalTrials.gov No. NCT02315118). Following the initial results of this ongoing trial, Unum recently announced the initiation of a clinical trial for patients with relapsed/refractory CD20+ B-NHL in which ACTR is durably expressed through viral delivery in autologous T-cells (ACTR087; ClinicalTrials.gov No. NCT02776813). Presentation Details:
Presentation Title: Targeting CD20+ Relapsed Refractory B-Cell
Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR)
Engineered Autologous T-Cells, in Combination with Rituximab
Presentation Title: ACTR Platform as an Adaptable, Universal
T-Cell Therapy That Can Target (News - Alert) Multiple Tumor Antigens to Overcome
Antigen Escape
Presentation Title: A First-in-Human Study of Autologous T
Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients
with B-Cell Non-Hodgkin Lymphoma (NHL) The posters will be posted on Unum's website following the presentations.
About Antibody-Coupled T-Cell Receptor (ACTR) Technology and ACTR087 In contrast to other T-cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum's approach is not restricted by a specific tumor cell antigen and, thus, may have applications for treating many different types of cancers when combined with the right antibody. Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087, Unum's most advanced product candidate, combines Unum's proprietary ACTR, with rituximab, an anti-CD20 antibody. The ACTR087 study will be the first clinical trial using a viral vector to permanently insert the ACTR gene into the genome of patient T-cells.
About Unum Therapeutics
View source version on businesswire.com: http://www.businesswire.com/news/home/20161204005003/en/ |